Loading…
Pluri Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -95.2% over 5Y.
today you would have $47.64▼ -95.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.01 | $2.99 | $4.28 | $4.64 | $7.52 | $11.68 | $56.56 | $31.52 | $63.20 | $110.40 | $114.40 | $90.40 | $200.00 | $281.60 | $255.20 | $199.20 | $114.40 | |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CTXRCitius Pharmaceuticals, Inc. | $0.60 | — | 0.2x | — | -81.09% | $16.53M |
| ADILAdial Pharmaceuticals Inc | $5.60 | — | — | — | -2011.64% | $16.43M |
| PLSMPulsenmore Ltd. | $2.57 | — | — | — | -17.62% | $16.71M |
| MDCXMedicus Pharma Ltd. | $0.26 |
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Company description provided by Yahoo Finance.
| P/S |
| 211.4x |
| 12.3x |
| 18.3x |
| 71.8x |
| 83.6x |
| 131.0x |
| — |
| 7855.3x |
| 1134.4x |
| 1794.8x |
| — |
| 40.5x |
| 235.9x |
| 457.0x |
| 306.8x |
| 211.4x |
| — |
| — |
| P/B | 3.0x | — | — | 243.9x | 1.8x | 1.0x | 0.8x | 3.2x | 2.8x | 3.1x | 4.4x | 3.0x | 1.5x | 2.8x | 3.6x | 4.0x | 2.4x | 7.5x |
| EPS | -$2.44 | -$3.56 | -$3.99 | -$6.24 | -$10.24 | -$14.16 | -$12.80 | -$23.20 | -$20.00 | -$25.60 | -$23.20 | -$28.00 | -$33.60 | -$30.40 | -$27.20 | -$28.00 | -$35.20 |
| Profit margin | -6511.08% | -2344.59% | -1690.34% | -6407.36% | -9867.94% | -17624.79% | — | -126747.83% | -65383.33% | -52252.00% | — | -816.51% | -6511.08% | -7106.07% | -3115.61% | -2066.20% | — | — |
| ROE | -87.25% | — | — | -21758.33% | -212.06% | -137.29% | -87.25% | -51.96% | -161.80% | -91.65% | -91.94% | -60.92% | -42.44% | -43.35% | -36.81% | -39.20% | -24.98% | -187.21% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -7446.11% |
| $16.28M |
| HKPDCellyan Biotechnology Co., Ltd | $0.35 | — | 0.9x | — | -15.59% | $16.84M |
| SCNXScienture Holdings, Inc. | $0.39 | — | 0.3x | — | -53.47% | $16.18M |